Treats postoperative nausea and vomiting. ANDA 219606, held by Bpi Labs. Trimethobenzamide Hydrochloride.
As of Nov 16, 2026, ANDA 219606 (Trimethobenzamide Hydrochloride), held by Bpi Labs, was first approved by FDA on Oct 16, 2025, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Trimethobenzamide Hydrochloride Injection is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 16, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Trimethobenzamide Hydrochloride100MG/ML · injectable;injection | Trimethobenzamide Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters